Sodium –glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor1 –5 and it confers an approximately two- to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD).1,6 –8 The prevalence of T2D among patients with HF is as high as 40 –45% and that of HF in patients with T2D is reported to be 10–23%.8 Patients wit
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research